Cochrane · systematic review · CD001191
Rivastigmine for Alzheimer's disease
Birks, JS, Chong, LY, Grimley Evans, J · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
8
current version
GRADE rated
8
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 8 · 100%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsRivastigmine compared to placebo for Alzheimer's disease
Population: patients with Alzheimer's disease, mild to moderate
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cognitive function (change from baseline at 26 weeks using ADAS‐Cog) Rivastigmine vs placebo | no estimate extracted | 6 studies · 3232 participants | Moderate |
Cognitive function (change from baseline at 26 weeks using MMSE) Rivastigmine vs placebo | no estimate extracted | 6 studies · 3205 participants | Moderate |
Activities of daily living (change from baseline at 26 weeks measured using various scales) Rivastigmine vs placebo | no estimate extracted | 6 studies · 3230 participants | Moderate |
Physician rated global impression tests (no change or worse compared with baseline, measured using Global Impression of Change at 26 weeks) Rivastigmine vs placebo | OR 0.68 [0.58, 0.8] | 7 studies · 3338 participants | Moderate |
Behavioural symptoms (change from baseline at 26 weeks measured using various scales) Rivastigmine vs placebo | no estimate extracted | 3 studies · 1529 participants | Moderate |
Acceptability of treatment (as measured by withdrawals from trials before end of treatment at 26 weeks) Rivastigmine vs placebo | OR 2.01 [1.71, 2.37] | 7 studies · 3569 participants | Moderate |
Incidence of adverse events (at least one adverse event by 26 weeks) Rivastigmine vs placebo | OR 2.14 [1.8, 2.53] | 7 studies · 3587 participants | Moderate |
Quality of life of patients or carers (measured using NPI‐D carer distress scale (change from baseline at 24 weeks) Rivastigmine vs placebo | no estimate extracted | 1 study · 529 participants | Moderate |